March 2024
Strategy
How to grow old gracefully (and preferably rich)...
Ahead of the final week of our event, focused on retirement planning, we consider some of the complexities of portfolio construction…
20 Mar
20 Mar
Strategy
Roller coaster ride
Thematic funds have seen significant outflows over the past two years…
13 Mar
13 Mar
Blog
Healthcare, UK valuations, and renewables
We take a look back at the final week of our ISA event…
28 Mar
28 Mar
Blog
Trend setters
We take a look at four mega-trends to future-proof your portfolio…
22 Mar
22 Mar
Features
Bouncing back to rude health
IBT is well-positioned to exploit the attractive valuations on offer in the biotech sector…
06 Mar
06 Mar
Features
Behind the trust: International Biotechnology Trust plc
Biotech companies stand to inject high returns and positive social impact into an investor’s portfolio and International Biotechnology Trust has an impressive track record of doing this with lower volatility than the index (NASDAQ Biotechnology Index), while paying a healthy dividend yield...
01 Mar
01 Mar
News
Results analysis: Bellevue Healthcare
Reviewing a tough financial year, but the last three months give grounds for optimism...
05 Mar
05 Mar
Fund Research
Bellevue Healthcare
BBH could be poised for strong performance as the rate cycle eases…
21 Mar
21 Mar
February 2024
Guides
Investing in biotechnology with investment trusts
How investment trusts can provide investors with access to the high-growth biotech sector…
27 Feb
27 Feb
Video
Talking Trusts: An introduction to investing in biotech with International Biotechnology Trust
We talk about what IBT offers for investors looking for exposure to the biotech sector…
27 Feb
27 Feb
Features
Waiting for the world to change
Closed-ended trusts are a simple way to access the attractive income and defensive potential of renewables infrastructure…
20 Feb
20 Feb
October 2023
Strategy
Computer says no
Markets are fixated on replacing humans with AI, rather than maintaining them with biotech. Could this be an opportunity to rotate profits?
18 Oct
18 Oct
Features
Staying on course in a volatile sector
IBT's has delivered superior returns with lower volatility than the wider market...
13 Oct
13 Oct
September 2023
Blog
Healthy fundamentals
Healthcare and biotech are out of favour despite the secular growth trends supporting them…
29 Sep
29 Sep
Trust Issues
A biotech bounce back? With IBT Manager Ailsa Craig - Podcast: Trust Issues #22
We talk the move to Schroders, managing risk, and reinvesting the proceeds of M&A activity...
28 Sep
28 Sep
Blog
Pizza Tiger
You don’t need to reinvent the wheel to deliver good returns on your investment...
15 Sep
15 Sep
Fund Research
International Biotechnology
IBT managers’ unique approach set to continue at Schroders…
15 Sep
15 Sep
August 2023
Strategy
Halfway there…investing on a prayer
We provide an update on our picks for 2023 and see which analysts' prayers are being answered…
23 Aug
23 Aug
Features
Not going away
Macro volatility won’t change a key long-term driver for Bellevue Healthcare...
04 Aug
04 Aug
Flash Update
Flash Update: International Biotechnology Trust
IBT moves to Schroders, with no change to team or process and the prospect of lower costs over time…
03 Aug
03 Aug
May 2023
Features
Is it time to buy healthcare?
Macro fears seem to have crimped valuations, despite the sector’s long-term growth prospects…
05 May
05 May
News
Results analysis: International Biotechnology Trust
IBT maintained its strong performance into the first half of its financial year…
03 May
03 May